title: A new look at tamoxifen: co-administration with letrozole in intrauterine insemination cycles.
abstract: OBJECTIVE
  To assess the effectiveness of tamoxifen administration with letrozole in the context of intrauterine insemination (IUI) cycles.
  
  
  METHODS
  This prospective double-blinded study included 130 patients. After randomization, 65 patients in group A received letrozole + tamoxifen and human menopausal gonadotropin (HMG), whereas 65 patients in group B received placebo instead of tamoxifen. In both groups, the parameters recorded were total number of follicles with ≥16 and 18 mm diameter, endometrial thickness and appearance, and total HMG administered. The results were compared between groups after single-stage IUI was performed.
  
  
  RESULTS
  Total dominant follicles in both groups were similar (mean number of follicles with diameter ≥16 and 18 mm was 1.5 ± 1.4 and 1.6 ± 1.1, respectively, in group A and 1.5 ± 1.1 and 1.6 ± 1, respectively, in group B; at the same time with less HMG usage in group A (255 ± 167 vs. 313 ± 174 IU), and higher pregnancy rate in group A (18.7 vs. 11.7 %); but none of them was statistically significant). Surprisingly, endometrial thickness was significantly higher in group A (7.7 ± 1.5 vs. 7 ± 1.3 mm; P value 0.008).
  
  
  CONCLUSIONS
  In addition to the efficacy of tamoxifen in co-administration with clomiphene citrate, it has promising effects with letrozole in induction of ovulation cycles with or without IUI.
authors.affiliation: Emam Khomeini Hospital, Ahvaz Jundishapur University of Medical Science (AJUMS), Ahvaz, Iran. e.pourmatroud@yahoo.com
authors.forename: Elham
authors.initials: E
authors.lastname: Pourmatroud
authors.forename: Mahvash
authors.initials: M
authors.lastname: Zargar
authors.forename: Roshan
authors.initials: R
authors.lastname: Nikbakht
authors.forename: Farideh
authors.initials: F
authors.lastname: Moramazi
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007246:Infertility / Q000628:therapy*; D007315:Insemination, Artificial; D000077289:Letrozole; D008596:Menotropins / Q000008:administration & dosage* / Q000627:therapeutic use; D009570:Nitriles / Q000008:administration & dosage* / Q000627:therapeutic use; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011446:Prospective Studies; D013629:Tamoxifen / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D005300:Fertility Agents, Female; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D008596:Menotropins; D000077289:Letrozole